Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Convalescent plasma donated by a recovered COVID-19 patient. Photo: Alex Edelman/AFP via Getty Images

A panel of experts at the National Institutes of Health on Tuesday weighed into the FDA's emergency use authorization (EUA) of convalescent plasma as a coronavirus treatment, stressing that "there are insufficient data to recommend either for or against" the use of plasma to treat COVID-19 patients.

Why it matters: President Trump and other officials pressured the FDA to grant an EUA for plasma despite warnings from public health experts, including those at the NIH, that data from randomized clinical trials was needed to determine the effectiveness of the treatment.

  • The objections against the authorization continued after FDA Commissioner Stephen Hahn oversold the benefits of convalescent plasma as a coronavirus treatment at a press conference with President Trump. He later apologized.

What they're saying: "There are currently no data from well-controlled, adequately powered randomized clinical trials that demonstrate the efficacy and safety of convalescent plasma for the treatment of COVID-19," the NIH COVID-19 Treatment Guidelines Panel wrote.

  • The panel added that convalescent plasma "should not be considered standard of care for the treatment of patients with COVID-19."

The bottom line: The NIH panel called for "prospective, well-controlled, adequately powered randomized trials" to "determine whether convalescent plasma is effective and safe for the treatment of COVID-19."

Go deeper: The tug of war over the FDA

Go deeper

Updated 6 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Sarah Grillo/Axios

  1. Health: How data and the pandemic have democratized the "high-performance lifestyle — "Twindemic" averted as flu reports plummet amid coronavirus crisis
  2. Vaccine: Pfizer begins study on 3rd vaccine dose as booster shot against new strains — Republicans are least likely to want the coronavirus vaccine
  3. U.S. news: California surpasses 50,000 deaths COVID-19 deaths, more than any other state — Jimmy and Rosalynn Carter return to church after receiving COVID-19 vaccines
  4. Local: Public transit ridership in Twin Cities dropped 53% amid pandemic — Data firm predicts "complete chaos" in next phases of Florida's vaccine rolloutAlaska Gov. Mike Dunleavy tests positive for the coronavirus
Dec 9, 2020 - Health

Pennsylvania governor tests positive for coronavirus

Gov. Tom Wolf at a press conference on Oct. 1. Photo: Pete Bannan/MediaNews Group/Daily Local News via Getty Images

Pennsylvania Gov. Tom Wolf (D), 72, tested positive for COVID-19 on Tuesday, and is experiencing no symptoms as he self-isolates, he tweeted Wednesday.

The big picture: Current coronavirus hospitalizations and cases are skyrocketing in Pennsylvania, as well as in many states across the U.S., per the COVID Tracking Project. Wolf tweeted on Tuesday that "hospitalizations are reaching critical levels" in his state.

Behind GameStop's latest stock surge

Illustration: Aïda Amer/Axios

Back in focus: The meme stock trade.

By the numbers: GameStop finished up 19%, after a wild day that saw shares spike as much as 80%.